BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 15, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Oral Relistor methylnaltrexone: Completed Phase III enrollment

Salix disclosed in its 2Q11 earnings that in July it completed enrollment of about 700 patients with chronic non-cancer pain in a double-blind, placebo-controlled, international Phase III trial to evaluate 3 doses of oral Relistor. Partner Progenics submitted an sNDA to FDA in June for subcutaneous...

Read the full 207 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >